176 related articles for article (PubMed ID: 27536436)
1. Safety, tolerability, pharmacokinetics and pharmacodynamics of belimumab in Japanese patients with mild-to-moderate systemic lupus erythematosus.
Yamada M; Akita M; Nakagawa T; Takahashi N; Endo A; Yoshida P
J Drug Assess; 2013; 2(1):40-8. PubMed ID: 27536436
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics, Pharmacodynamics and Safety of Belimumab in Chinese Patients with Systemic Lupus Erythematosus: A Phase I, Open-Label Study.
Zhang J; Wan W; Miao L; Wu J; Dong J; Shen Y; Xiong C; Li C; Xue Y; Cao G; Ma P
Rheumatol Ther; 2020 Mar; 7(1):191-200. PubMed ID: 31953740
[TBL] [Abstract][Full Text] [Related]
3. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus.
Furie R; Stohl W; Ginzler EM; Becker M; Mishra N; Chatham W; Merrill JT; Weinstein A; McCune WJ; Zhong J; Cai W; Freimuth W;
Arthritis Res Ther; 2008; 10(5):R109. PubMed ID: 18786258
[TBL] [Abstract][Full Text] [Related]
4. Comparison of intravenous and subcutaneous exposure supporting dose selection of subcutaneous belimumab systemic lupus erythematosus Phase 3 program.
Yapa SW; Roth D; Gordon D; Struemper H
Lupus; 2016 Nov; 25(13):1448-1455. PubMed ID: 27072354
[TBL] [Abstract][Full Text] [Related]
5. Belimumab: anti-BLyS human monoclonal antibody, anti-BLyS monoclonal antibody, BmAb, human monoclonal antibody to B-lymphocyte stimulator.
Drugs R D; 2008; 9(3):197-202. PubMed ID: 18457473
[TBL] [Abstract][Full Text] [Related]
6. The pharmacokinetics and safety profiles of belimumab after single subcutaneous and intravenous doses in healthy Japanese volunteers.
Shida Y; Takahashi N; Sakamoto T; Ino H; Endo A; Hirama T
J Clin Pharm Ther; 2014 Feb; 39(1):97-101. PubMed ID: 24117862
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and Safety of Intravenous and Subcutaneous Auto-injector Single-dose Belimumab in Healthy Chinese Volunteers: A phase 1, Randomized, Open-label Study.
Meng X; Wang Q; Wu S; Pu D; Zhang A; Fang S; Zhou X; Lu H
Rheumatol Ther; 2021 Dec; 8(4):1711-1724. PubMed ID: 34554352
[TBL] [Abstract][Full Text] [Related]
8. A 6-month open-label extension study of the safety and efficacy of subcutaneous belimumab in patients with systemic lupus erythematosus.
Doria A; Bass D; Schwarting A; Hammer A; Gordon D; Scheinberg M; Fox NL; Groark J; Stohl W; Kleoudis C; Roth D
Lupus; 2018 Aug; 27(9):1489-1498. PubMed ID: 29807477
[TBL] [Abstract][Full Text] [Related]
9. Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol.
Teng YKO; Bruce IN; Diamond B; Furie RA; van Vollenhoven RF; Gordon D; Groark J; Henderson RB; Oldham M; Tak PP
BMJ Open; 2019 Mar; 9(3):e025687. PubMed ID: 30898822
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of intravenous belimumab in Japanese patients with systemic lupus erythematosus: A subgroup analysis of a phase 3 randomized placebo-controlled trial.
Tanaka Y; Bass D; Chu M; Egginton S; Ji B; Struemper H; Roth D
Mod Rheumatol; 2019 May; 29(3):452-460. PubMed ID: 29792370
[TBL] [Abstract][Full Text] [Related]
11. Organ system improvements in Japanese patients with systemic lupus erythematosus treated with belimumab: A subgroup analysis from a phase 3 randomized placebo-controlled trial.
Tanaka Y; Bass D; Chu M; Egginton S; Ji B; Roth D
Mod Rheumatol; 2020 Mar; 30(2):313-320. PubMed ID: 31199180
[No Abstract] [Full Text] [Related]
12. Pharmacokinetics of Belimumab in Children With Systemic Lupus Erythematosus.
Dimelow R; Ji B; Struemper H
Clin Pharmacol Drug Dev; 2021 Jun; 10(6):622-633. PubMed ID: 33245847
[TBL] [Abstract][Full Text] [Related]
13. Safety of belimumab in adult patients with systemic lupus erythematosus: Results of a large integrated analysis of controlled clinical trial data.
Wallace DJ; Atsumi T; Daniels M; Hammer A; Meizlik P; Quasny H; Schwarting A; Zhang F; Roth DA
Lupus; 2022 Nov; 31(13):1649-1659. PubMed ID: 36206400
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study.
Stohl W; Schwarting A; Okada M; Scheinberg M; Doria A; Hammer AE; Kleoudis C; Groark J; Bass D; Fox NL; Roth D; Gordon D
Arthritis Rheumatol; 2017 May; 69(5):1016-1027. PubMed ID: 28118533
[TBL] [Abstract][Full Text] [Related]
15. Efficacy, pharmacokinetic and pharmacodynamic profile of belimumab for systemic lupus erythematosus.
Jordan NP; D'Cruz DP
Expert Opin Drug Metab Toxicol; 2015; 11(10):1635-45. PubMed ID: 26327145
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of biologic therapies for systemic lupus erythematosus treatment: systematic review and meta-analysis.
Borba HH; Wiens A; de Souza TT; Correr CJ; Pontarolo R
BioDrugs; 2014 Apr; 28(2):211-28. PubMed ID: 24190520
[TBL] [Abstract][Full Text] [Related]
17. Belimumab: a BLyS-specific inhibitor for systemic lupus erythematosus.
Wiglesworth AK; Ennis KM; Kockler DR
Ann Pharmacother; 2010 Dec; 44(12):1955-61. PubMed ID: 21081710
[TBL] [Abstract][Full Text] [Related]
18. Long-term safety and efficacy of belimumab in Japanese patients with SLE: A 7-year open-label continuation study.
Tanaka Y; Curtis P; DeRose K; Kurrasch R; Kinoshita K; Tanaka R; Yamazaki Y; Roth DA
Mod Rheumatol; 2023 Jan; 33(1):122-133. PubMed ID: 34915574
[TBL] [Abstract][Full Text] [Related]
19. Elevated BLyS levels in patients with systemic lupus erythematosus: Associated factors and responses to belimumab.
Roth DA; Thompson A; Tang Y; Hammer AE; Molta CT; Gordon D
Lupus; 2016 Apr; 25(4):346-54. PubMed ID: 26385220
[TBL] [Abstract][Full Text] [Related]
20. Belimumab: review of use in systemic lupus erythematosus.
Boyce EG; Fusco BE
Clin Ther; 2012 May; 34(5):1006-22. PubMed ID: 22464040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]